Omecamtiv mecarbil
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510321

CAS#: 873697-71-3

Description: Omecamtiv mecarbil, also known as CK-1827452, is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure. Omecamtiv Mecarbil specifically targets and activates myocardial ATPase and improves energy utilization. Omecamtiv Mecarbil improves systolic function by increasing the systolic ejection duration/stroke volume, without consuming more ATP energy, oxygen or altering intracellular calcium levels causing an overall improvement in cardiac efficiency. (source: http://en.wikipedia.org/wiki/Omecamtiv_mecarbil)


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 3450
Size
Price

25mg
USD 250
200mg
USD 1250
2g
USD 5250
Size
Price

50mg
USD 450
500mg
USD 2050
5g
USD 8650

Omecamtiv mecarbil, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 510321
Name: Omecamtiv mecarbil
CAS#: 873697-71-3
Chemical Formula: C20H24FN5O3
Exact Mass: 401.1863
Molecular Weight: 401.43
Elemental Analysis: C, 59.84; H, 6.03; F, 4.73; N, 17.45; O, 11.96


Synonym: Omecamtiv mecarbil; CK1827452; CK 1827452; CK1827452.

IUPAC/Chemical Name: methyl 4-(2-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate

InChi Key: RFUBTTPMWSKEIW-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)

SMILES Code: O=C(N1CCN(CC2=CC=CC(NC(NC3=CC=C(C)N=C3)=O)=C2F)CC1)OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

 1: Spinarova L, Spinar J. Pharmacotherapy of dilated cardiomyopathy. Curr Pharm Des. 2014;21(4):449-58. PubMed PMID: 25483945.

2: Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina. JACC Heart Fail. 2014 Nov 11. pii: S2213-1779(14)00379-5. doi: 10.1016/j.jchf.2014.07.009. [Epub ahead of print] PubMed PMID: 25453536.

3: McNeice AH, McAleavey NM, Menown IB. Advances in clinical cardiology. Adv Ther. 2014 Aug;31(8):837-60. doi: 10.1007/s12325-014-0141-9. Epub 2014 Jul 30. PubMed PMID: 25074280.

4: Wang Y, Ajtai K, Burghardt TP. Analytical comparison of natural and pharmaceutical ventricular myosin activators. Biochemistry. 2014 Aug 19;53(32):5298-306. doi: 10.1021/bi500730t. Epub 2014 Aug 7. PubMed PMID: 25068717; PubMed Central PMCID: PMC4139156.

5: Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knöll R, Leite-Moreira AF, Lourenço AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014 May;16(5):494-508. doi: 10.1002/ejhf.62. Epub 2014 Mar 17. PubMed PMID: 24639064.

6: Shintani SA, Oyama K, Kobirumaki-Shimozawa F, Ohki T, Ishiwata S, Fukuda N. Sarcomere length nanometry in rat neonatal cardiomyocytes expressed with α-actinin-AcGFP in Z discs. J Gen Physiol. 2014 Apr;143(4):513-24. doi: 10.1085/jgp.201311118. Epub 2014 Mar 17. PubMed PMID: 24638993; PubMed Central PMCID: PMC3971663.

7: Valentova M, von Haehling S. An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert Opin Investig Drugs. 2014 Apr;23(4):573-8. doi: 10.1517/13543784.2014.881799. Epub 2014 Feb 4. Review. PubMed PMID: 24490905.

8: Pollesello P. Drug discovery and development for acute heart failure drugs: are expectations too high? Int J Cardiol. 2014 Mar 1;172(1):11-3. doi: 10.1016/j.ijcard.2013.12.136. Epub 2014 Jan 4. PubMed PMID: 24472177.

9: Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail. 2013 Jun;19(6):371-89. doi: 10.1016/j.cardfail.2013.04.002. Review. PubMed PMID: 23743486.

10: Zhang M, Mou T, Zhao Z, Peng C, Ma Y, Fang W, Zhang X. Synthesis and 18F-labeling of the analogues of Omecamtiv Mecarbil as a potential cardiac myosin imaging agent with PET. Nucl Med Biol. 2013 Jul;40(5):689-96. doi: 10.1016/j.nucmedbio.2013.02.013. Epub 2013 Apr 6. PubMed PMID: 23566883.